Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Respiratory Tract Viral InfectionsHuman Metapneumovirus (hMPV) InfectionParainfluenza (PIV) InfectionRespiratory Syncytial Viral (RSV) InfectionInfluenza Infection
Interventions
BIOLOGICAL

ALVR106

Infusion, visually identical to placebo

BIOLOGICAL

Placebo

Infusion, visually identical to ALVR106

Trial Locations (21)

14203

Roswell Park Comprehensive Cancer Center, Buffalo

23298

Virginia Commonwealth University, Richmond

27157

Wake Forest, Winston-Salem

27599

University of North Carolina - Lineberger Comprehensive Cancer Center, Chapel Hill

27708

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

30342

Northside Hospital, Atlanta

32610

University of Florida - Division of Hematology & Oncology, Gainesville

33136

University of Miami - Sylvester Cancer Center, Miami

37212

Vanderbilt University Cancer Center, Nashville

44195

The Cleveland Clinic Foundation, Cleveland

52242

University of Iowa, Iowa City

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

77030

Baylor College of Medicine, Houston

MD Anderson Cancer Center, Houston

MD Anderson, Houston

85260

Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale

91010

City of Hope, Duarte

98109

Fred Hutchinson Cancer Research Center, Seattle

64116.

University of Kansas Cancer Center, Kansas City

02215

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AlloVir

INDUSTRY

NCT04933968 - Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant | Biotech Hunter | Biotech Hunter